New pill aims to tackle fatty liver and diabetes at once
NCT ID NCT05464784
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an oral drug called MN-001 (tipelukast) in 40 adults with non-alcoholic fatty liver disease, type 2 diabetes, and high triglycerides. Participants take either the drug or a placebo daily for 24 weeks. The study measures changes in liver fat and blood fat levels to see if the drug is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MN-001 (tipelukast)
What this could lead to
If it works, this could point toward a new oral treatment that reduces liver fat and triglycerides in people with fatty liver disease and diabetes.
What could go wrong
This is a small, early-phase trial with only 40 people. The drug may not show enough benefit or could cause side effects. Success in this trial does not guarantee approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jubilee Clinical Research, Inc.
Las Vegas, Nevada, 89106, United States
-
Pinnacle Clinical Research at South Texas Research Institute
Edinburg, Texas, 78539, United States